Valcyte: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

27 March 2024

20 March 2024

  • curprev 02:2602:26, 20 March 2024‎ Lazy talk contribs‎ 1,104 bytes +1,104‎ Created page with "{{TreatmentInfo |drug_name=Valganciclovir (Valcyte) |FDA_approval=Yes (for CMV infections) |used_for=Investigational use in glioblastoma due to potential effects against CMV positive tumors |clinical_trial_phase=Investigational, including early clinical trials |common_side_effects=Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects |OS_without=Median survival with standard treatment: 17.4 months |OS_with=Post-hoc analysis with at least s..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Valcyte"